Stellar growth continues at Planet, the New York-headquartered multi-currency payment and data processing specialist.
Founded by chairman and CEO Philip Beck, Planet, floated on AIM in 2006, is the company behind a global payments and data processing platform able to process different currencies, helping ‘acquiring’ banks (processors of credit card sales for ‘merchants’) to reduce expenses, and international ‘merchants’ – retailers, restaurateurs, hoteliers – to grow sales and profits.
In a positive recent trading missive, Beck said calendar 2009 sales (results are out in March) would show growth of more than 30% to over $47m (£29m), driven by eye-catching growth in core multi-currency processing income across the US, Greater China, India, Malaysia and Taiwan. Furthermore, fourth quarter sales increased by around 19%, both year-on-year and on the third quarter of 2009, to around $14m.
Planet, which topped up its cash coffers with a £2.4m placing at 80p last year, also said it expects to report positive EBITDA for 2009. Beck, in buoyant mood, attributes these strong financials, achieved despite the effects of tough economic conditions on key travel and hospitality markets, to ‘the continued growth of our business and the operating leverage inherent in the Planet Payment business model’. And he predicts further good top line growth in 2010, based on a 'robust pipeline of acquiring bank and merchant rollouts in new and existing markets’.
Analysts are looking for $1.1m of positive EBITDA for 2009, though pre-tax profits will still elude. However on the $68.7m sales forecast for 2010, EBITDA should come in at $6.2m and Planet could post pre-tax profits of $5m, giving EPS of 7.6p. On those estimates, the shares are selling for less than 14 times earnings, undemanding given growth rates and global prospects.
We remain big believers in Planet’s long-term fundamentals and the shares, backed by Growth Company Investor at 59p in October, should have further to go. Nevertheless, given stock market unpredictability, some partial profit taking might be prudent at this stage.
Market cap: £27.63m
PE Forecast: 13.8
Share price: 105p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.